These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 35182510)

  • 1. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study.
    Abdelhak A; Petermeier F; Benkert P; Schädelin S; Oechtering J; Maleska Maceski A; Kabesch M; Geis T; Laub O; Leipold G; Gobbi C; Zecca C; Green A; Tumani H; Willemse E; Wiendl H; Granziera C; Kappos L; Leppert D; Waubant E; Wellmann S; Kuhle J
    Lancet Neurol; 2023 Sep; 22(9):826-833. PubMed ID: 37524100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study.
    Hegen H; Berek K; Bsteh G; Auer M; Altmann P; Di Pauli F; Grams A; Milosavljevic D; Ponleitner M; Poskaite P; Schnabl C; Wurth S; Zinganell A; Berger T; Walde J; Deisenhammer F
    EBioMedicine; 2023 May; 91():104573. PubMed ID: 37086651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
    Monreal E; Fernández-Velasco JI; García-Sánchez MI; Sainz de la Maza S; Llufriu S; Álvarez-Lafuente R; Casanova B; Comabella M; Ramió-Torrentà L; Martínez-Rodríguez JE; Brieva L; Saiz A; Eichau S; Cabrera-Maqueda JM; Villarrubia N; Espiño M; Pérez-Miralles F; Montalbán X; Tintoré M; Quiroga-Varela A; Domínguez-Mozo MI; Rodríguez-Jorge F; Chico-García JL; Lourido D; Álvarez-Cermeño JC; Masjuan J; Costa-Frossard L; Villar LM
    JAMA Neurol; 2023 Apr; 80(4):397-403. PubMed ID: 36848127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study.
    Meyer T; Salkic E; Grehl T; Weyen U; Kettemann D; Weydt P; Günther R; Lingor P; Koch JC; Petri S; Hermann A; Prudlo J; Großkreutz J; Baum P; Boentert M; Metelmann M; Norden J; Cordts I; Weishaupt JH; Dorst J; Ludolph A; Koc Y; Walter B; Münch C; Spittel S; Dreger M; Maier A; Körtvélyessy P
    Eur J Neurol; 2023 Jun; 30(6):1600-1610. PubMed ID: 36899448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.
    Reinert MC; Benkert P; Wuerfel J; Michalak Z; Ruberte E; Barro C; Huppke P; Stark W; Kropshofer H; Tomic D; Leppert D; Kuhle J; Brück W; Gärtner J
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32404429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
    Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice.
    Valentino P; Marnetto F; Martire S; Malucchi S; Bava CI; Popovic M; Bertolotto A
    Mult Scler Relat Disord; 2021 Sep; 54():103090. PubMed ID: 34182224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH
    Mult Scler; 2020 Nov; 26(13):1670-1681. PubMed ID: 31610732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
    Sharmin S; Roos I; Malpas CB; Iaffaldano P; Simone M; Filippi M; Kubala Havrdova E; Ozakbas S; Brescia Morra V; Alroughani R; Zaffaroni M; Patti F; Eichau S; Salemi G; Di Sapio A; Inglese M; Portaccio E; Trojano M; Amato MP; Kalincik T; ;
    Lancet Child Adolesc Health; 2024 May; 8(5):348-357. PubMed ID: 38547883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients.
    Valentino P; Malucchi S; Bava CI; Martire S; Capobianco M; Malentacchi M; Sperli F; Oggero A; Di Sapio A; Bertolotto A
    Mult Scler Relat Disord; 2023 Sep; 77():104893. PubMed ID: 37481820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P
    Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.